Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Clin Cases. May 16, 2018; 6(5): 74-83
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Table 1 Baseline characteristics of the study population
CharacteristicsSorafenib + TACE (n = 38)TACE (n = 29)P value
Gender, Male/Female24 (63.2%)/14 (36.8%)18 (62.1%)/11 (37.9%)> 0.05
Age (mean ± SD, yr)52 ± 551 ± 6> 0.05
ECOG PS 0/1/2/3/4 (%)38 (100%)/0 (0%)/0/(0%) 0/(0%)29 (100%)/0 (0%)/0/(0%) 0/(0%)> 0.05
Child-Pugh A/B25 (65.8%)/13 (34.2%)19 (65.5%)/10 (34.5%)> 0.05
Tumor diameter (cm) ≥ 6/< 614 (36.8%)/24 (63.2%)10 (34.5%)/19 (65.5%)> 0.05
Serum albumin (g/L) ≥ 35/< 3520 (52.6%)/18 (47.4%)16 (55.2%)/13 (44.8%)> 0.05
Serum bilirubin (umol/L) ≥ 20/< 2011 (28.9%)/27 (71.1%)8 (27.6%)/21 (72.4%)> 0.05
LDH (U/L) ≥ 245/< 24523 (60.5%)/15 (39.5%)16 (55.2%)/13 (44.8%)> 0.05
AFP (ng/mL) ≥ 200/< 20025 (65.8%)/13 (34.2%)19 (65.5%)/10 (34.5%)> 0.05
Number of TACE ≥ 2/< 219 (50.0%)/19 (50.0%)14 (48.3%)/15 (51.7%)> 0.05